A clear salt solution is gently pumped into the eye through one of the ports to maintain eye pressure during surgery and to replace the removed vitreous. Diabetic retinopathy is the most common diabetic eye disease and a leading cause of blindness in the United States. This form of retinopathy is considered mild. Food and Drug Administration FDA for treating DBE. However, they have thin, fragile walls. A vitrectomy is the surgical removal of the vitreous gel in the canter of the eye. Anti-VEGF Injection Therapy. Some of the kinds of damage that your doctor may see in your retina are hypertensive retinopathy, a complication of high blood pressure hypertension, and diabetic retinopathy, a complication of long-term diabetes. no datahttp://dclakers.com/advisingeyesurgeon/2016/11/04/simple-information-on-handy-eye-surgery-solutions/High blood pressure damages the blood vessel walls, causing them to thicken and narrow. Trauma, especially to the head, and several diseases may cause Purtscher’s retinopathy Hyperviscosity-related retinopathy as seen in disorders which cause paraproteinemia Many types of retinopathy are proliferative, most often resulting from neovascularization or blood vessel overgrowth.
When.he.oal of the operation is to remove blood from the eye, it usually works. If they break open, blood can leak into the middle part of your eye in front of the retina and change your vision . What is diabetic macular enema DBE? Fortunately, with regular, proper eye care and treatment when necessary, the incidence of severe vision loss has been greatly reduced. These treatments appear promising, but more study is needed. Your eye doctor will examine your eyes. Diabetic retinopathy is treated in many ways depending on the stage of the disease and the specific problem that requires attention. Prevention of retinopathy is very important for people with diabetes and hypertension . The symptoms can occur hours to days after the incident.
In the third quarter, as Dan alluded to, we had significant seasonality in July, with the doctors being out of the office on vacation. But we rebounded and had strong sales in August and September. And if you look at the US sales, end user demand — so when I say end user demand, what the doctors or the pharmacies are buying from the distributors — we actually had a slight uptick in that demand in the third quarter compared to the second. So trend is heading in the right direction, certainly, but it’s a little bit distorted because of our small size right now, impacted by the distributor stocking and the timing of that. ——————————————————————————– Boris Peaker, Cowen & Co. – Analyst  ——————————————————————————– Great. And my last question is there’s certainly a lot of discussion in terms of pricing these days. What is your strategy for price increases going forward? ——————————————————————————– Rick Eiswirth, Alimera Sciences, Inc. – President & CFO  ——————————————————————————– Boris, I don’t anticipate that we would have price increases going forward, because the majority of our sales are done from a buy-and-bill model. Reimbursement to the doctors is based on a trailing average sales price.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/edited-transcript-alim-earnings-conference-035754940.html